CARsgen's Claudin18.2 CAR T-Cell Candidate Granted US RMAT Designation

CARsgen Therapeutics, a Shanghai CAR-T-company, was granted Regenerative Medicine Advanced Therapy (RMAT) designation in the US for CT041, an autologous CAR T-cell product. CT041 is being developed for advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJ) with a Claudin18.2-positive tumor. The RMAT designation means CT041 has the benefits of Fast Track and Breakthrough Therapy designations. CT041 is the only CLDN18.2-targeted CAR T-cell candidate currently with IND approvals in the US , China and Canada . More details.... Stock Symbol: (HK: 2171) Share this with colleagues: // //